Aurora A kinase inhibitor
Showing 1 - 25 of >10,000
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung
Recruiting
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- +8 more
- Aurora A Kinase Inhibitor LY3295668
- Osimertinib
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)
Not yet recruiting
- Liver Cancer
- +2 more
- Lenvatinib Oral Product Plus VIC1911
-
Shanghai, ChinaDeparment of Liver Surgery, Ren Ji Hospital, School of Medicine,
Jan 30, 2023
Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)
Active, not recruiting
- Non Small Cell Lung Cancer
- +5 more
-
Orange, California
- +13 more
Nov 7, 2022
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Necitumumab
- Osimertinib
-
Duarte, California
- +14 more
Jan 27, 2023
Amyotrophic Lateral Sclerosis Trial in Australia, United States (Fasudil (WP-0512))
Recruiting
- Amyotrophic Lateral Sclerosis
- Fasudil (WP-0512)
-
Phoenix, Arizona
- +11 more
Oct 28, 2022
NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)
Completed
- Non-Small Cell Lung Cancer ALK-positive
- +4 more
- PF-02341066
- +2 more
-
Orange, California
- +28 more
Feb 15, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +4 more
- Alisertib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- combination therapy with no MEKi
- +3 more
- (no location specified)
Nov 29, 2022
Acute Megakaryoblastic Leukemia, Myelofibrosis, Primary Myelofibrosis Trial in Miami, Chicago, Rochester (Alisertib, Laboratory
Active, not recruiting
- Acute Megakaryoblastic Leukemia
- +2 more
- Alisertib
- +2 more
-
Miami, Florida
- +2 more
May 4, 2021
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase
Recruiting
- Liver Transplant
- PVHA or TACE
-
Shanghai, Shanghai, ChinaThe value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022
Non-Hodgkins Lymphoma, Solid Tumor Trial in Vancouver, Ottawa (Aurora kinase inhibitor AT9283)
Completed
- Non-Hodgkins Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific
- Aurora kinase inhibitor AT9283
-
Vancouver, British Columbia, Canada
- +1 more
Apr 6, 2020
Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- (no location specified)
Aug 1, 2023
Neuroblastoma Trial in Worldwide (LY3295668 Erbumine, Topotecan, Cyclophosphamide)
Active, not recruiting
- Neuroblastoma
- LY3295668 Erbumine
- +2 more
-
San Francisco, California
- +21 more
Aug 17, 2022
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer Trial in Aurora
Completed
- Adenocarcinoma of the Lung
- +7 more
-
Aurora, ColoradoUniversity of Colorado Cancer Center
Jan 19, 2022
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic
Active, not recruiting
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma
- +25 more
- Laboratory Biomarker Analysis
- +3 more
-
Torrance, California
- +6 more
Jan 12, 2023
Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)
Recruiting
- Liver Neoplasms
- Tislelizumab plus tyrosine kinase inhibitor
-
Beijing, Beijing, China302 Hospital
Sep 22, 2023
Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals
Not yet recruiting
- Preterm Labor
- (no location specified)
May 9, 2023
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung
Active, not recruiting
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- +5 more
-
Sacramento, California
- +17 more
Aug 2, 2022
Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)
Not yet recruiting
- Acute Myeloid Leukemia
- Lymphoma, Mantle-Cell
- (no location specified)
Dec 22, 2022